Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses NEOG in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NEOG in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| John Adent | $810,000 | $0 | $1,800,000 | $4,200,000 | $0 | $0 | $14,891 | $6,824,891 |
| President & Chief Executive Officer | ||||||||
| David Naemura | 571,500 | 0 | 836,400 | 1,254,600 | 0 | 0 | 17,681 | 2,680,181 |
| Chief Financial Officer & Chief Operating Officer | ||||||||
| Douglas Jones | 464,322 | 0 | 720,000 | 1,080,000 | 0 | 0 | 12,139 | 2,276,461 |
| Chief Operating Officer (Retired) | ||||||||
| Amy Rocklin | 447,694 | 0 | 520,000 | 780,000 | 0 | 0 | 20,073 | 1,767,767 |
| Chief Legal & Compliance Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| John Adent | $6,824,891 | — | — | — |
| David Naemura | 2,680,181 | — | — | — |
| Douglas Jones | 2,276,461 | — | — | — |
| Amy Rocklin | 1,767,767 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| James C. Borel | Director | 2025-10-07 | A | 2,071 | $6 | $11,660 | Common | Form 4 ↗ |
| Catherine E. Woteki | Director | 2025-10-07 | A | 2,071 | 6 | 11,660 | Common | Form 4 ↗ |
| Douglas Jones | Former COO | 2025-10-07 | A | 12,940 | 6 | 72,852 | Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-07 | A | 32,936 | 6 | 185,430 | Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-07 | D | 32,936 | 6 | 185,430 | Derivative, Class A Common | Form 4 ↗ |
| James P. Tobin | Director | 2025-10-07 | A | 2,071 | 6 | 11,660 | Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2025-10-07 | D | 2,071 | 6 | 11,660 | Derivative, Class A Common | Form 4 ↗ |
| Amy Rocklin | Chief Legal Officer | 2025-10-07 | D | 3,534 | 6 | 19,896 | Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-07 | D | 9,297 | 6 | 52,342 | Common | Form 4 ↗ |
| Douglas Jones | Former COO | 2025-10-07 | D | 6,329 | 6 | 35,632 | Common | Form 4 ↗ |
| William T. Boehm | Director | 2025-10-07 | A | 2,071 | 6 | 11,660 | Common | Form 4 ↗ |
| William T. Boehm | Director | 2025-10-07 | D | 2,071 | 6 | 11,660 | Derivative, Class A Common | Form 4 ↗ |
| James C. Borel | Director | 2025-10-07 | D | 2,071 | 6 | 11,660 | Derivative, Class A Common | Form 4 ↗ |
| Amy Rocklin | Chief Legal Officer | 2025-10-07 | A | 9,036 | 5 | 48,433 | Common | Form 4 ↗ |
| Ronald D. Green | Director | 2025-10-07 | D | 2,071 | 6 | 11,660 | Derivative, Class A Common | Form 4 ↗ |
| Raphael A. Rodriguez | Director | 2025-10-07 | D | 2,071 | 6 | 11,660 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2025-10-07 | A | 2,071 | 6 | 11,660 | Common | Form 4 ↗ |
| Douglas Jones | Former COO | 2025-10-07 | D | 12,940 | 6 | 72,852 | Derivative, Class A Common | Form 4 ↗ |
| Aashima Gupta | Director | 2025-10-07 | A | 2,071 | 6 | 11,660 | Common | Form 4 ↗ |
| Aashima Gupta | Director | 2025-10-07 | D | 2,071 | 6 | 11,660 | Derivative, Class A Common | Form 4 ↗ |
| Amy Rocklin | Chief Legal Officer | 2025-10-07 | D | 9,036 | 6 | 50,873 | Derivative, Class A Common | Form 4 ↗ |
| Catherine E. Woteki | Director | 2025-10-07 | D | 2,071 | 6 | 11,660 | Derivative, Class A Common | Form 4 ↗ |
| James P. Tobin | Director | 2025-10-07 | D | 2,071 | 6 | 11,660 | Derivative, Class A Common | Form 4 ↗ |
| Raphael A. Rodriguez | Director | 2025-10-07 | A | 2,071 | 6 | 11,660 | Common | Form 4 ↗ |
| Ronald D. Green | Director | 2025-10-07 | A | 2,071 | 6 | 11,660 | Common | Form 4 ↗ |
| Amy Rocklin | Chief Legal Officer | 2025-10-13 | A | 294 | 6 | 1,776 | Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-13 | D | 865 | 6 | 5,225 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-10-13 | — | 1,077 | — | ~6,505 | 2 insiders, 2 accrual rows | ||
| Douglas Jones | Former COO | 2025-10-13 | D | 383 | 6 | 2,313 | Common | Form 4 ↗ |
| Amy Rocklin | Chief Legal Officer | 2025-10-13 | D | 115 | 6 | 695 | Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-13 | A | 3,063 | 6 | 18,501 | Common | Form 4 ↗ |
| Douglas Jones | Former COO | 2025-10-13 | A | 783 | 6 | 4,729 | Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-13 | D | 3,063 | 6 | 18,501 | Derivative, Class A Common | Form 4 ↗ |
| Aashima Gupta | Director | 2025-10-23 | A | 50,814 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Catherine E. Woteki | Director | 2025-10-23 | A | 19,769 | 6 | 119,998 | Common | Form 4 ↗ |
| Andrea F. Wainer | Director | 2025-10-23 | A | 19,769 | 6 | 119,998 | Common | Form 4 ↗ |
| Raphael A. Rodriguez | Director | 2025-10-23 | A | 19,769 | 6 | 119,998 | Common | Form 4 ↗ |
| Raphael A. Rodriguez | Director | 2025-10-23 | A | 50,814 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ronald D. Green | Director | 2025-10-23 | A | 19,769 | 6 | 119,998 | Common | Form 4 ↗ |
| Ronald D. Green | Director | 2025-10-23 | A | 50,814 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2025-10-23 | A | 50,814 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thierry L. Bernard | Director | 2025-10-23 | A | 50,814 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James C. Borel | Director | 2025-10-23 | A | 50,814 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thierry L. Bernard | Director | 2025-10-23 | A | 19,769 | 6 | 119,998 | Common | Form 4 ↗ |
| Catherine E. Woteki | Director | 2025-10-23 | A | 50,814 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Aashima Gupta | Director | 2025-10-23 | A | 19,769 | 6 | 119,998 | Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2025-10-23 | A | 19,769 | 6 | 119,998 | Common | Form 4 ↗ |
| James C. Borel | Director | 2025-10-23 | A | 19,769 | 6 | 119,998 | Common | Form 4 ↗ |
| Andrea F. Wainer | Director | 2025-10-23 | A | 50,814 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Avi Pelossof | Director | 2025-10-24 | A | 19,386 | 6 | 119,999 | Common | Form 4 ↗ |
| Avi Pelossof | Director | 2025-10-24 | A | 49,929 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ronald D. Green | Director | 2025-10-27 | D | 1,777 | 6 | 11,000 | Derivative, Class A Common | Form 4 ↗ |
| James C. Borel | Director | 2025-10-27 | A | 2,025 | 6 | 12,535 | Common | Form 4 ↗ |
| David Naemura | Chief Financial Officer | 2025-10-27 | A | 15,504 | 6 | 95,970 | Common | Form 4 ↗ |
| Aashima Gupta | Director | 2025-10-27 | A | 1,777 | 6 | 11,000 | Common | Form 4 ↗ |
| David Naemura | Chief Financial Officer | 2025-10-27 | D | 15,504 | 6 | 95,970 | Derivative, Class A Common | Form 4 ↗ |
| William T. Boehm | Director | 2025-10-27 | D | 3,553 | 6 | 21,567 | Derivative, Class A Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-27 | D | 38,759 | 6 | 239,918 | Derivative, Class A Common | Form 4 ↗ |
| James C. Borel | Director | 2025-10-27 | A | 1,777 | 6 | 11,000 | Common | Form 4 ↗ |
| James C. Borel | Director | 2025-10-27 | D | 1,777 | 6 | 11,000 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2025-10-27 | A | 1,777 | 6 | 11,000 | Common | Form 4 ↗ |
| Aashima Gupta | Director | 2025-10-27 | D | 1,777 | 6 | 11,000 | Derivative, Class A Common | Form 4 ↗ |
| Raphael A. Rodriguez | Director | 2025-10-27 | D | 1,777 | 6 | 11,000 | Derivative, Class A Common | Form 4 ↗ |
| James P. Tobin | Director | 2025-10-27 | D | 1,777 | 6 | 11,000 | Derivative, Class A Common | Form 4 ↗ |
| Catherine E. Woteki | Director | 2025-10-27 | D | 1,777 | 6 | 11,000 | Derivative, Class A Common | Form 4 ↗ |
| Amy Rocklin | Chief Legal Officer | 2025-10-27 | A | 9,474 | 6 | 58,644 | Common | Form 4 ↗ |
| Amy Rocklin | Chief Legal Officer | 2025-10-27 | D | 2,085 | 6 | 12,906 | Common | Form 4 ↗ |
| Amy Rocklin | Chief Legal Officer | 2025-10-27 | D | 9,474 | 6 | 58,644 | Derivative, Class A Common | Form 4 ↗ |
| Douglas Jones | Former COO | 2025-10-27 | D | 3,481 | 6 | 21,547 | Common | Form 4 ↗ |
| Douglas Jones | Former COO | 2025-10-27 | D | 15,504 | 6 | 95,970 | Derivative, Class A Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-27 | A | 38,759 | 6 | 239,918 | Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-27 | D | 8,527 | 6 | 52,782 | Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2025-10-27 | A | 2,025 | 6 | 12,535 | Common | Form 4 ↗ |
| James C. Borel | Director | 2025-10-27 | D | 2,025 | 6 | 12,535 | Derivative, Class A Common | Form 4 ↗ |
| Raphael A. Rodriguez | Director | 2025-10-27 | A | 1,777 | 6 | 11,000 | Common | Form 4 ↗ |
| James P. Tobin | Director | 2025-10-27 | A | 1,777 | 6 | 11,000 | Common | Form 4 ↗ |
| Catherine E. Woteki | Director | 2025-10-27 | A | 1,777 | 6 | 11,000 | Common | Form 4 ↗ |
| William T. Boehm | Director | 2025-10-27 | A | 3,553 | 6 | 21,567 | Common | Form 4 ↗ |
| Douglas Jones | Former COO | 2025-10-27 | A | 15,504 | 6 | 95,970 | Common | Form 4 ↗ |
| David Naemura | Chief Financial Officer | 2025-10-27 | D | 4,261 | 6 | 26,376 | Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2025-10-27 | D | 1,777 | 6 | 11,000 | Derivative, Class A Common | Form 4 ↗ |
| Ronald D. Green | Director | 2025-10-27 | A | 1,777 | 6 | 11,000 | Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2025-10-27 | D | 2,025 | 6 | 12,535 | Derivative, Class A Common | Form 4 ↗ |
| Mikhael Nassif | Director | 2025-11-03 | A | 177 | 6 | 1,106 | Common, indirect | Form 4 ↗ |
| Richard Bryan Riggsbee | CFO | 2025-11-03 | A | 178,855 | 6 | 1,124,998 | Common | Form 4 ↗ |
| Richard Bryan Riggsbee | CFO | 2025-11-03 | A | 459,713 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Naemura | Former CFO | 2025-12-01 | A | 12,912 | 6 | 77,214 | Common | Form 4 ↗ |
| David Naemura | Former CFO | 2025-12-01 | D | 3,548 | 6 | 21,217 | Common | Form 4 ↗ |
| David Naemura | Former CFO | 2025-12-01 | D | 12,912 | 6 | 77,214 | Derivative, Class A Common | Form 4 ↗ |
| Tamara A. Ranalli | Senior Vice President | 2026-01-07 | A | 50,813 | 7 | 375,000 | Common | Form 4 ↗ |
| Tamara A. Ranalli | Senior Vice President | 2026-01-07 | A | 50,813 | 7 | 375,000 | Common | Form 4 ↗ |
| Tamara A. Ranalli | Senior Vice President | 2026-01-07 | A | 50,813 | 7 | 375,000 | Common | Form 4 ↗ |
| Tamara A. Ranalli | Senior Vice President | 2026-01-07 | A | 130,605 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamara A. Ranalli | Senior Vice President | 2026-01-07 | A | 261,210 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mikhael Nassif | Director | 2026-01-16 | A | 137 | 9 | 1,279 | Common, indirect | Form 4 ↗ |
| Mikhael Nassif | Director | 2026-01-26 | A | 24 | 10 | 240 | Common, indirect | Form 4 ↗ |
| Mikhael Nassif | Director | 2026-01-26 | A | 25 | 10 | 246 | Common, indirect | Form 4 ↗ |
| Mikhael Nassif | Director | 2026-02-17 | A | 23 | 11 | 252 | Common, indirect | Form 4 ↗ |
| Jennifer Evans Stacey | Chief Legal Officer | 2026-05-01 | A | 89,520 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jennifer Evans Stacey | Chief Legal Officer | 2026-05-01 | A | 39,349 | 10 | 374,996 | Common | Form 4 ↗ |
| John Patrick Moylan | Chief Accounting Officer | 2026-05-04 | A | 4,558 | 10 | 43,438 | Common | Form 4 ↗ |
| John Patrick Moylan | Chief Accounting Officer | 2026-05-04 | D | 4,558 | 10 | 43,438 | Derivative, Class A Common | Form 4 ↗ |
| John Patrick Moylan | Chief Accounting Officer | 2026-05-04 | D | 1,568 | 10 | 14,943 | Common | Form 4 ↗ |
| Amy Rocklin | Former Chief Legal Officer | 2026-05-18 | D | 35,183 | 9 | 326,850 | Derivative, Class A Common | Form 4 ↗ |
| Amy Rocklin | Former Chief Legal Officer | 2026-05-18 | D | 10,241 | 9 | 95,139 | Common | Form 4 ↗ |
| Amy Rocklin | Former Chief Legal Officer | 2026-05-18 | A | 35,183 | 9 | 326,850 | Common | Form 4 ↗ |
| John Patrick Moylan | Chief Accounting Officer | 2026-06-03 | D | 2,553 | 9 | 22,339 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| James C. Borel | Director | 2025-10-07 | A | 2,071 | $6 | $11,660 | Common | Form 4 ↗ |
| Catherine E. Woteki | Director | 2025-10-07 | A | 2,071 | 6 | 11,660 | Common | Form 4 ↗ |
| Douglas Jones | Former COO | 2025-10-07 | A | 12,940 | 6 | 72,852 | Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-07 | A | 32,936 | 6 | 185,430 | Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-07 | D | 32,936 | 6 | 185,430 | Derivative, Class A Common | Form 4 ↗ |
| James P. Tobin | Director | 2025-10-07 | A | 2,071 | 6 | 11,660 | Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2025-10-07 | D | 2,071 | 6 | 11,660 | Derivative, Class A Common | Form 4 ↗ |
| Amy Rocklin | Chief Legal Officer | 2025-10-07 | D | 3,534 | 6 | 19,896 | Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-07 | D | 9,297 | 6 | 52,342 | Common | Form 4 ↗ |
| Douglas Jones | Former COO | 2025-10-07 | D | 6,329 | 6 | 35,632 | Common | Form 4 ↗ |
| William T. Boehm | Director | 2025-10-07 | A | 2,071 | 6 | 11,660 | Common | Form 4 ↗ |
| William T. Boehm | Director | 2025-10-07 | D | 2,071 | 6 | 11,660 | Derivative, Class A Common | Form 4 ↗ |
| James C. Borel | Director | 2025-10-07 | D | 2,071 | 6 | 11,660 | Derivative, Class A Common | Form 4 ↗ |
| Amy Rocklin | Chief Legal Officer | 2025-10-07 | A | 9,036 | 5 | 48,433 | Common | Form 4 ↗ |
| Ronald D. Green | Director | 2025-10-07 | D | 2,071 | 6 | 11,660 | Derivative, Class A Common | Form 4 ↗ |
| Raphael A. Rodriguez | Director | 2025-10-07 | D | 2,071 | 6 | 11,660 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2025-10-07 | A | 2,071 | 6 | 11,660 | Common | Form 4 ↗ |
| Douglas Jones | Former COO | 2025-10-07 | D | 12,940 | 6 | 72,852 | Derivative, Class A Common | Form 4 ↗ |
| Aashima Gupta | Director | 2025-10-07 | A | 2,071 | 6 | 11,660 | Common | Form 4 ↗ |
| Aashima Gupta | Director | 2025-10-07 | D | 2,071 | 6 | 11,660 | Derivative, Class A Common | Form 4 ↗ |
| Amy Rocklin | Chief Legal Officer | 2025-10-07 | D | 9,036 | 6 | 50,873 | Derivative, Class A Common | Form 4 ↗ |
| Catherine E. Woteki | Director | 2025-10-07 | D | 2,071 | 6 | 11,660 | Derivative, Class A Common | Form 4 ↗ |
| James P. Tobin | Director | 2025-10-07 | D | 2,071 | 6 | 11,660 | Derivative, Class A Common | Form 4 ↗ |
| Raphael A. Rodriguez | Director | 2025-10-07 | A | 2,071 | 6 | 11,660 | Common | Form 4 ↗ |
| Ronald D. Green | Director | 2025-10-07 | A | 2,071 | 6 | 11,660 | Common | Form 4 ↗ |
| Amy Rocklin | Chief Legal Officer | 2025-10-13 | A | 294 | 6 | 1,776 | Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-13 | D | 865 | 6 | 5,225 | Common | Form 4 ↗ |
| Douglas Jones | Former COO | 2025-10-13 | D | 783 | 6 | 4,729 | Derivative, Class A Common | Form 4 ↗ |
| Douglas Jones | Former COO | 2025-10-13 | D | 383 | 6 | 2,313 | Common | Form 4 ↗ |
| Amy Rocklin | Chief Legal Officer | 2025-10-13 | D | 115 | 6 | 695 | Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-13 | A | 3,063 | 6 | 18,501 | Common | Form 4 ↗ |
| Douglas Jones | Former COO | 2025-10-13 | A | 783 | 6 | 4,729 | Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-13 | D | 3,063 | 6 | 18,501 | Derivative, Class A Common | Form 4 ↗ |
| Amy Rocklin | Chief Legal Officer | 2025-10-13 | D | 294 | 6 | 1,776 | Derivative, Class A Common | Form 4 ↗ |
| Aashima Gupta | Director | 2025-10-23 | A | 50,814 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Catherine E. Woteki | Director | 2025-10-23 | A | 19,769 | 6 | 119,998 | Common | Form 4 ↗ |
| Andrea F. Wainer | Director | 2025-10-23 | A | 19,769 | 6 | 119,998 | Common | Form 4 ↗ |
| Raphael A. Rodriguez | Director | 2025-10-23 | A | 19,769 | 6 | 119,998 | Common | Form 4 ↗ |
| Raphael A. Rodriguez | Director | 2025-10-23 | A | 50,814 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ronald D. Green | Director | 2025-10-23 | A | 19,769 | 6 | 119,998 | Common | Form 4 ↗ |
| Ronald D. Green | Director | 2025-10-23 | A | 50,814 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2025-10-23 | A | 50,814 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thierry L. Bernard | Director | 2025-10-23 | A | 50,814 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James C. Borel | Director | 2025-10-23 | A | 50,814 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thierry L. Bernard | Director | 2025-10-23 | A | 19,769 | 6 | 119,998 | Common | Form 4 ↗ |
| Catherine E. Woteki | Director | 2025-10-23 | A | 50,814 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Aashima Gupta | Director | 2025-10-23 | A | 19,769 | 6 | 119,998 | Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2025-10-23 | A | 19,769 | 6 | 119,998 | Common | Form 4 ↗ |
| James C. Borel | Director | 2025-10-23 | A | 19,769 | 6 | 119,998 | Common | Form 4 ↗ |
| Andrea F. Wainer | Director | 2025-10-23 | A | 50,814 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Avi Pelossof | Director | 2025-10-24 | A | 19,386 | 6 | 119,999 | Common | Form 4 ↗ |
| Avi Pelossof | Director | 2025-10-24 | A | 49,929 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ronald D. Green | Director | 2025-10-27 | D | 1,777 | 6 | 11,000 | Derivative, Class A Common | Form 4 ↗ |
| James C. Borel | Director | 2025-10-27 | A | 2,025 | 6 | 12,535 | Common | Form 4 ↗ |
| David Naemura | Chief Financial Officer | 2025-10-27 | A | 15,504 | 6 | 95,970 | Common | Form 4 ↗ |
| Aashima Gupta | Director | 2025-10-27 | A | 1,777 | 6 | 11,000 | Common | Form 4 ↗ |
| David Naemura | Chief Financial Officer | 2025-10-27 | D | 15,504 | 6 | 95,970 | Derivative, Class A Common | Form 4 ↗ |
| William T. Boehm | Director | 2025-10-27 | D | 3,553 | 6 | 21,567 | Derivative, Class A Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-27 | D | 38,759 | 6 | 239,918 | Derivative, Class A Common | Form 4 ↗ |
| James C. Borel | Director | 2025-10-27 | A | 1,777 | 6 | 11,000 | Common | Form 4 ↗ |
| James C. Borel | Director | 2025-10-27 | D | 1,777 | 6 | 11,000 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2025-10-27 | A | 1,777 | 6 | 11,000 | Common | Form 4 ↗ |
| Aashima Gupta | Director | 2025-10-27 | D | 1,777 | 6 | 11,000 | Derivative, Class A Common | Form 4 ↗ |
| Raphael A. Rodriguez | Director | 2025-10-27 | D | 1,777 | 6 | 11,000 | Derivative, Class A Common | Form 4 ↗ |
| James P. Tobin | Director | 2025-10-27 | D | 1,777 | 6 | 11,000 | Derivative, Class A Common | Form 4 ↗ |
| Catherine E. Woteki | Director | 2025-10-27 | D | 1,777 | 6 | 11,000 | Derivative, Class A Common | Form 4 ↗ |
| Amy Rocklin | Chief Legal Officer | 2025-10-27 | A | 9,474 | 6 | 58,644 | Common | Form 4 ↗ |
| Amy Rocklin | Chief Legal Officer | 2025-10-27 | D | 2,085 | 6 | 12,906 | Common | Form 4 ↗ |
| Amy Rocklin | Chief Legal Officer | 2025-10-27 | D | 9,474 | 6 | 58,644 | Derivative, Class A Common | Form 4 ↗ |
| Douglas Jones | Former COO | 2025-10-27 | D | 3,481 | 6 | 21,547 | Common | Form 4 ↗ |
| Douglas Jones | Former COO | 2025-10-27 | D | 15,504 | 6 | 95,970 | Derivative, Class A Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-27 | A | 38,759 | 6 | 239,918 | Common | Form 4 ↗ |
| John Edward Adent | Former CEO | 2025-10-27 | D | 8,527 | 6 | 52,782 | Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2025-10-27 | A | 2,025 | 6 | 12,535 | Common | Form 4 ↗ |
| James C. Borel | Director | 2025-10-27 | D | 2,025 | 6 | 12,535 | Derivative, Class A Common | Form 4 ↗ |
| Raphael A. Rodriguez | Director | 2025-10-27 | A | 1,777 | 6 | 11,000 | Common | Form 4 ↗ |
| James P. Tobin | Director | 2025-10-27 | A | 1,777 | 6 | 11,000 | Common | Form 4 ↗ |
| Catherine E. Woteki | Director | 2025-10-27 | A | 1,777 | 6 | 11,000 | Common | Form 4 ↗ |
| William T. Boehm | Director | 2025-10-27 | A | 3,553 | 6 | 21,567 | Common | Form 4 ↗ |
| Douglas Jones | Former COO | 2025-10-27 | A | 15,504 | 6 | 95,970 | Common | Form 4 ↗ |
| David Naemura | Chief Financial Officer | 2025-10-27 | D | 4,261 | 6 | 26,376 | Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2025-10-27 | D | 1,777 | 6 | 11,000 | Derivative, Class A Common | Form 4 ↗ |
| Ronald D. Green | Director | 2025-10-27 | A | 1,777 | 6 | 11,000 | Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2025-10-27 | D | 2,025 | 6 | 12,535 | Derivative, Class A Common | Form 4 ↗ |
| Mikhael Nassif | Director | 2025-11-03 | A | 177 | 6 | 1,106 | Common, indirect | Form 4 ↗ |
| Richard Bryan Riggsbee | CFO | 2025-11-03 | A | 178,855 | 6 | 1,124,998 | Common | Form 4 ↗ |
| Richard Bryan Riggsbee | CFO | 2025-11-03 | A | 459,713 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Naemura | Former CFO | 2025-12-01 | A | 12,912 | 6 | 77,214 | Common | Form 4 ↗ |
| David Naemura | Former CFO | 2025-12-01 | D | 3,548 | 6 | 21,217 | Common | Form 4 ↗ |
| David Naemura | Former CFO | 2025-12-01 | D | 12,912 | 6 | 77,214 | Derivative, Class A Common | Form 4 ↗ |
| Tamara A. Ranalli | Senior Vice President | 2026-01-07 | A | 50,813 | 7 | 375,000 | Common | Form 4 ↗ |
| Tamara A. Ranalli | Senior Vice President | 2026-01-07 | A | 50,813 | 7 | 375,000 | Common | Form 4 ↗ |
| Tamara A. Ranalli | Senior Vice President | 2026-01-07 | A | 50,813 | 7 | 375,000 | Common | Form 4 ↗ |
| Tamara A. Ranalli | Senior Vice President | 2026-01-07 | A | 130,605 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tamara A. Ranalli | Senior Vice President | 2026-01-07 | A | 261,210 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mikhael Nassif | Director | 2026-01-16 | A | 137 | 9 | 1,279 | Common, indirect | Form 4 ↗ |
| Mikhael Nassif | Director | 2026-01-26 | A | 24 | 10 | 240 | Common, indirect | Form 4 ↗ |
| Mikhael Nassif | Director | 2026-01-26 | A | 25 | 10 | 246 | Common, indirect | Form 4 ↗ |
| Mikhael Nassif | Director | 2026-02-17 | A | 23 | 11 | 252 | Common, indirect | Form 4 ↗ |
| Jennifer Evans Stacey | Chief Legal Officer | 2026-05-01 | A | 89,520 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jennifer Evans Stacey | Chief Legal Officer | 2026-05-01 | A | 39,349 | 10 | 374,996 | Common | Form 4 ↗ |
| John Patrick Moylan | Chief Accounting Officer | 2026-05-04 | A | 4,558 | 10 | 43,438 | Common | Form 4 ↗ |
| John Patrick Moylan | Chief Accounting Officer | 2026-05-04 | D | 4,558 | 10 | 43,438 | Derivative, Class A Common | Form 4 ↗ |
| John Patrick Moylan | Chief Accounting Officer | 2026-05-04 | D | 1,568 | 10 | 14,943 | Common | Form 4 ↗ |
| Amy Rocklin | Former Chief Legal Officer | 2026-05-18 | D | 35,183 | 9 | 326,850 | Derivative, Class A Common | Form 4 ↗ |
| Amy Rocklin | Former Chief Legal Officer | 2026-05-18 | D | 10,241 | 9 | 95,139 | Common | Form 4 ↗ |
| Amy Rocklin | Former Chief Legal Officer | 2026-05-18 | A | 35,183 | 9 | 326,850 | Common | Form 4 ↗ |
| John Patrick Moylan | Chief Accounting Officer | 2026-06-03 | D | 2,553 | 9 | 22,339 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| David Naemura | OPTION | 2025-01-16 | — | — | 45,150 | — | $291,000 |
| Douglas Jones | Options/SARs | 2024-08-15 | — | — | 201,764 | — | 1,800,000 |
| David Naemura | Options/SARs | 2024-08-15 | — | — | 201,764 | — | 1,800,000 |
| Amy Rocklin | Options/SARs | 2024-08-15 | — | — | 145,718 | — | 1,300,000 |
| John Adent | Options/SARs | 2024-08-15 | — | — | 784,636 | — | 6,000,000 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| David Naemura | $0 | $0 | $291,000 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| John Adent | Option | 30,750 | 34.15 | — |
| Douglas Jones | Option | 8,835 | 28.4 | — |
| Douglas Jones | Option | 201,764 | 16.79 | — |
| David Naemura | Option | 374,130 | 15.48 | — |
| Amy Rocklin | Option | 5,890 | 28.4 | — |
| Amy Rocklin | Option | 40,179 | 13.28 | — |
| Amy Rocklin | Option | 145,718 | 16.79 | — |
| David Naemura | RSU | 300,109 | — | 1,758,632 |
| Douglas Jones | RSU | 213,815 | — | 1,252,954 |
| Douglas Jones | RSU | 42,883 | — | 251,294 |
| David Naemura | RSU | 42,883 | — | 251,294 |
| Douglas Jones | RSU | 31,008 | — | 181,707 |
| David Naemura | RSU | 31,008 | — | 181,707 |
| Amy Rocklin | RSU | 30,971 | — | 181,490 |
| Amy Rocklin | RSU | 18,949 | — | 111,041 |
| David Naemura | RSU | 12,912 | — | 75,664 |
| Douglas Jones | RSU | 12,378 | — | 72,535 |
| David Naemura | RSU | 10,034 | — | 58,799 |
| Amy Rocklin | RSU | 9,036 | — | 52,951 |
| John Adent | RSU | 2,816 | — | 16,502 |
| David Naemura | Option | 45,150 | 11.6 | — |
| Douglas Jones | RSU | 1,690 | — | 9,903 |
| Douglas Jones | RSU | 1,567 | — | 9,183 |
| Amy Rocklin | RSU | 1,127 | — | 6,604 |
| Amy Rocklin | RSU | 588 | — | 3,446 |
| Douglas Jones | RSU | 562 | — | 3,293 |
| Douglas Jones | Option | 3,954 | 34.15 | — |
| Douglas Jones | Option | 9,887 | 40.85 | — |
| David Naemura | Option | 57,471 | 15.49 | — |
| David Naemura | Option | 201,764 | 16.79 | — |
| Amy Rocklin | Option | 73,150 | 15.48 | — |
| John Adent | RSU | 914,161 | — | 5,356,977 |
| John Adent | RSU | 107,207 | — | 628,233 |
| John Adent | RSU | 77,519 | — | 454,261 |
| Amy Rocklin | RSU | 131,328 | — | 769,582 |
| John Adent | RSU | 30,120 | — | 176,503 |
| John Adent | RSU | 6,127 | — | 35,904 |
| John Adent | RSU | 4,226 | — | 24,764 |
| John Adent | Option | 465,501 | 15.48 | — |
| John Adent | Option | 60,143 | 40.85 | — |
| John Adent | Option | 34,357 | 28.4 | — |
| John Adent | Option | 208,336 | 13.28 | — |
| John Adent | Option | 784,636 | 16.79 | — |
| Douglas Jones | Option | 55,035 | 13.28 | — |
| Douglas Jones | Option | 119,700 | 15.48 | — |
| Amy Rocklin | Option | 3,708 | 40.85 | — |
An important element of our overall compensation philosophy is to deliver a total compensation opportunity that is competitive with the market median with the ability to differentiate based on individual performance, future potential, strategic needs, labor market for talent and other individual and company-specific attributes.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Farient Advisors, LLC |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-10-23 | 167,126,873 | 17,679,601 | 412,667 | 90.43% | Passed |
| 2024 | 2024-10-24 | 96,518,858 | 101,431,438 | 677,525 | 48.76% | Failed |
| 2023 | 2023-10-25 | 188,942,194 | 6,399,654 | 294,342 | 96.72% | Passed |
| 2022 | 2022-10-06 | 74,522,788 | 3,427,649 | 311,060 | 95.6% | Passed |
| 2021 | 2021-10-07 | 91,114,077 | 3,300,741 | 204,853 | 96.5% | Passed |
| 2020 | 2020-10-08 | 45,126,250 | 869,819 | 109,282 | 98.11% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-10-23 | 90.43%a |
| 2024 | 2024-10-24 | 48.76%b |
| 2023 | 2023-10-25 | 96.72%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast so will not have any effect on the outcome of this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast so will not have any effect on the outcome of this proposal.”.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 152 : 1 |
|---|---|
| CEO total compensation | $8,863,146 |
| Median employee compensation | $58,231 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| James C. BorelIndependent · Board Chair · Audit · Governance (Chair) | $127,500 | $82,500 | $82,500 | $0 | $0 | $292,500 |
| William T. Boehm, Ph.DIndependent · Audit (Chair) · Compensation · Not standing for re-election · Departed during FY | 82,500 | 82,500 | 82,500 | 0 | 0 | 247,500 |
| James P. TobinIndependent · Departed during FY | 80,000 | 82,500 | 82,500 | 0 | 0 | 245,000 |
| Catherine E. Woteki, Ph.DIndependent · Compensation (Chair) · Science, Technology and Innovation | 77,500 | 82,500 | 82,500 | 0 | 0 | 242,500 |
| Ronald D. Green, Ph.DIndependent · Governance · Science, Technology and Innovation (Chair) | 77,500 | 82,500 | 82,500 | 0 | 0 | 242,500 |
| Jeffrey D. CapelloIndependent · Audit · Compensation | 72,500 | 82,500 | 82,500 | 0 | 0 | 237,500 |
| Raphael A. RodriguezIndependent · Compensation · Science, Technology and Innovation | 70,000 | 82,500 | 82,500 | 0 | 0 | 235,000 |
| Aashima GuptaIndependent · Governance · Science, Technology and Innovation | 70,000 | 82,500 | 82,500 | 0 | 0 | 235,000 |
| Thierry L. BernardIndependent · Compensation · Governance | 64,167 | 81,150 | 81,150 | 0 | 0 | 226,467 |
| John E. AdentEmployee director · Not standing for re-election · Departed during FY | 0 | 0 | 0 | — | 0 | 0 |
| Andrea F. WainerIndependent · Audit · Science, Technology and Innovation · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Avi PelossofIndependent · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Mikhael NassifEmployee director · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $55,000 |
|---|---|
| Annual equity retainer | $240,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 7,500 / 7,500 |
| Stock ownership guideline | 5x annual cash retainer |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $721,667 |
| Equity awards (grant-date value) | $741,150 |
| All other compensation | $0 |
| Total cost of the board | $1,462,817 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Neogen names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Neogen.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exact Sciences Corporation | 2024 | Kevin Conroy | $1,083,368 | $13,496,138 | $0 | $712,329 | $15,539,378 |
| 2 | Charles River Laboratories, Inc. | 2025 | James Foster | 1,545,636 | 11,601,089 | 0 | 2,182,666 | 15,435,220 |
| 3 | Natera, Inc. | 2025 | Steven Chapman | 853,710 | 12,979,558 | 0 | 1,114,151 | 14,957,319 |
| 4 | IDEXX Laboratories, Inc. | 2025 | Jonathan Mazelsky | 1,150,000 | 5,399,881 | 5,400,001 | 2,593,000 | 14,580,122 |
| 5 | Waters Corporation | 2025 | Udit Batra | 1,150,000 | 7,430,247 | 2,999,922 | 2,371,875 | 13,973,044 |
| 6 | QuidelOrtho Corporation | 2025 | Brian Blaser | 1,000,000 | 8,965,822 | 0 | 1,274,500 | 11,255,782 |
| 7 | Sotera Health Company | 2025 | Michael Petras | 1,130,699 | 8,022,400 | 0 | 1,484,890 | 10,656,063 |
| 8 | Azenta, Inc. | 2025 | John Marotta | 900,000 | 8,386,297 | 0 | 1,063,656 | 10,371,414 |
| 9 | Maravai LifeScience Holdings, Inc. | 2025 | Bernd Brust | 388,863 | 7,660,000 | 1,460,000 | 425,343 | 10,129,708 |
| 10 | NeoGenomics, Inc. | 2025 | Tony Zook | 601,539 | 3,999,997 | 3,998,235 | 513,400 | 9,127,092 |
| 11 | Guardant Health, Inc. | 2025 | AmirAli Talasaz | 1 | 8,647,709 | 0 | 0 | 8,661,227 |
| 12 | Bio-Techne Corporation | 2025 | Kim Kelderman | 936,000 | 3,929,942 | 1,932,848 | 1,318,917 | 8,151,181 |
| 13 | Bio-Rad Laboratories, Inc. | 2025 | Norman Schwartz | 1,089,877 | 4,856,574 | 1,458,975 | 562,088 | 7,995,841 |
| 14 | Neogen | 2025 | John Adent | 810,000 | 1,800,000 | 4,200,000 | 0 | 6,824,891 |
| 15 | Mettler-Toledo International, Inc. | 2025 | Patrick Kaltenbach | 1,145,999 | 3,267,808 | 1,635,033 | 462,984 | 6,741,212 |
| 16 | Repligen Corporation | 2025 | Olivier Loeillot | 860,000 | 3,374,853 | 1,095,626 | 774,000 | 6,114,771 |
| 17 | Bruker Corporation | 2025 | Frank Laukien | 976,554 | 1,623,407 | 1,488,109 | 587,270 | 4,706,388 |
| 18 | OraSure Technologies, Inc. | 2025 | Carrie Eglinton Manner | 721,000 | 3,394,188 | 0 | 173,040 | 4,292,228 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Neogen | not disclosed | PSU 50 · Option 50 | not disclosed | Farient Advisors, LLC |
| Azenta, Inc. | 107.4% | PSU 50 · RSU 50 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
| Bio-Rad Laboratories, Inc. | not disclosed | not disclosed | not disclosed | Compensia, Inc. |
| Bio-Techne Corporation | 128.1% | PSU 50 · Options 25 · RSU 25 | No | Aon Talent |
| Bruker Corporation | 43.0% | RSU 52 · Options 48 | not disclosed | Aon's Human Capital Solutions Practice |
| Charles River Laboratories, Inc. | 139% | PSU 60 · RSU 40 | Yes — Three-year rTSR | Pay Governance |
| Exact Sciences Corporation | 47% | PSU 60 · RSU 40 | No | Aon |
| Guardant Health, Inc. | 140% | PSU 50 · RSU 50 | No | Aon |
| IDEXX Laboratories, Inc. | 140% | Options 50 · PSU 50 | No | Farient |
| Maravai LifeScience Holdings, Inc. | not disclosed | not disclosed | No | Meridian Compensation Partners, LLC |
| Mettler-Toledo International, Inc. | 80% | PSU 33 · RSU 33 · Options 33 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners (PM&P) |
| Natera, Inc. | 131.1% | PSU 50 · RSU 50 | No | Aon |
| NeoGenomics, Inc. | 60% | RSU 50 · Options 50 | not disclosed | WTW |
| OraSure Technologies, Inc. | 24.0% | RSU 50 · PSU 50 | Yes — Relative TSR performance vs peer group | Pay Governance LLC |
| QuidelOrtho Corporation | 127% | PSU 60 · RSU 40 | Yes — Total Shareholder Return (TSR) | Compensia |
| Repligen Corporation | 100% | RSU 50 · PSU 25 · Options 25 | No | Meridian Compensation Partners, LLC |
| Sotera Health Company | 103% | PSU 40 · RSU 40 · Other 20 | No | Exequity |
| Waters Corporation | 110% | PSU 50 · Options 35 · RSU 15 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, John Adent | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “Summary Compensation Table”. As printed: 6,824,891. Filing ↗machine: r3 · c31 · span 1277142–1277151 |
| 2 | Section 01, David Naemura | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “Summary Compensation Table”. As printed: 2,680,181. Filing ↗machine: r9 · c31 · span 1353342–1353351 |
| 3 | Section 01, Douglas Jones | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “Summary Compensation Table”. As printed: 2,276,461. Filing ↗machine: r6 · c31 · span 1315254–1315263 |
| 4 | Section 01, Amy Rocklin | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “Summary Compensation Table”. As printed: 1,767,767. Filing ↗machine: r12 · c31 · span 1391244–1391253 |
| 5 | Section 03, David Naemura OPTION | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “ESPP” · grants of plan-based awards table. Filing ↗machine: t94 · r7 · c33 · span 1504963–1504970 |
| 6 | Section 03, Douglas Jones Options/SARs | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “LTI V” · grants of plan-based awards table. Filing ↗machine: t81 · r4 · c3 · span 1069342–1069349 |
| 7 | Section 03, David Naemura Options/SARs | DEF 14A | — | 0000950170-25-114381 | Section “LTI V” · grants of plan-based awards table. Filing ↗machine: t80 · r5 · c6 · span 1050913–1050922 |
| 8 | Section 03, Amy Rocklin Options/SARs | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “LTI V” · grants of plan-based awards table. Filing ↗machine: t80 · r6 · c3 · span 1053263–1053272 |
| 9 | Section 03, John Adent Options/SARs | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “LTI V” · grants of plan-based awards table. Filing ↗machine: t81 · r3 · c3 · span 1065274–1065281 |
| 10 | Section 07, pay ratio | DEF 14A | 2026-08-21 | 0001193125-26-360742 | Section “CEO Pay Ratio”. As printed: 152 : 1. Filing ↗ |
| 11 | Section 08, James C. Borel | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “Director Compensation”. As printed: 292,500. Filing ↗machine: t117 · r5 · c18 · span 2437292–2437299 |
| 12 | Section 08, William T. Boehm, Ph.D | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “Director Compensation”. As printed: 247,500. Filing ↗machine: t117 · r4 · c18 · span 2429712–2429719 |
| 13 | Section 08, James P. Tobin | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “Director Compensation”. As printed: 245,000. Filing ↗machine: t117 · r10 · c18 · span 2475204–2475211 |
| 14 | Section 08, Catherine E. Woteki, Ph.D | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “Director Compensation”. As printed: 242,500. Filing ↗machine: t117 · r11 · c18 · span 2483460–2483467 |
| 15 | Section 08, Ronald D. Green, Ph.D | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “Director Compensation”. As printed: 242,500. Filing ↗machine: t117 · r7 · c18 · span 2452462–2452469 |
| 16 | Section 08, Jeffrey D. Capello | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “Director Compensation”. As printed: 237,500. Filing ↗machine: t117 · r6 · c18 · span 2444875–2444882 |
| 17 | Section 08, Raphael A. Rodriguez | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “Director Compensation”. As printed: 235,000. Filing ↗machine: t117 · r9 · c18 · span 2467625–2467632 |
| 18 | Section 08, Aashima Gupta | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “Director Compensation”. As printed: 235,000. Filing ↗machine: t117 · r8 · c18 · span 2460040–2460047 |
| 19 | Section 08, Thierry L. Bernard | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “Director Compensation”. As printed: 226,467. Filing ↗machine: t117 · r3 · c18 · span 2422124–2422131 |
| 20 | Section 08, John E. Adent | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 21 | Section 08, Andrea F. Wainer | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 22 | Section 08, Avi Pelossof | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 23 | Section 08, Mikhael Nassif | DEF 14A | 2025-09-12 | 0000950170-25-114381 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 24 | Section 02, James C. Borel 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000036 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Catherine E. Woteki 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000042 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Douglas Jones 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, John Edward Adent 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, John Edward Adent 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, James P. Tobin 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Jeffrey D. Capello 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Amy Rocklin 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, John Edward Adent 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Douglas Jones 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, William T. Boehm 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, William T. Boehm 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, James C. Borel 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000036 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Amy Rocklin 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Ronald D. Green 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000038 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Raphael A. Rodriguez 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000040 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Jeffrey D. Capello 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Douglas Jones 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Aashima Gupta 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Aashima Gupta 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Amy Rocklin 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Catherine E. Woteki 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000042 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, James P. Tobin 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Raphael A. Rodriguez 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000040 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Ronald D. Green 2025-10-07 | Form 4 | 2025-10-09 | 0000711377-25-000038 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Amy Rocklin 2025-10-13 | Form 4 | 2025-10-14 | 0000711377-25-000048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, John Edward Adent 2025-10-13 | Form 4 | 2025-10-14 | 0000711377-25-000046 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Douglas Jones 2025-10-13 | Form 4 | 2025-10-14 | 0000711377-25-000047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Douglas Jones 2025-10-13 | Form 4 | 2025-10-14 | 0000711377-25-000047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Amy Rocklin 2025-10-13 | Form 4 | 2025-10-14 | 0000711377-25-000048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, John Edward Adent 2025-10-13 | Form 4 | 2025-10-14 | 0000711377-25-000046 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Douglas Jones 2025-10-13 | Form 4 | 2025-10-14 | 0000711377-25-000047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, John Edward Adent 2025-10-13 | Form 4 | 2025-10-14 | 0000711377-25-000046 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Amy Rocklin 2025-10-13 | Form 4 | 2025-10-14 | 0000711377-25-000048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Aashima Gupta 2025-10-23 | Form 4 | 2025-10-27 | 0000711377-25-000053 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Catherine E. Woteki 2025-10-23 | Form 4 | 2025-10-27 | 0000711377-25-000056 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Andrea F. Wainer 2025-10-23 | Form 4 | 2025-10-27 | 0000711377-25-000055 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Raphael A. Rodriguez 2025-10-23 | Form 4 | 2025-10-27 | 0000711377-25-000054 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Raphael A. Rodriguez 2025-10-23 | Form 4 | 2025-10-27 | 0000711377-25-000054 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Ronald D. Green 2025-10-23 | Form 4 | 2025-10-27 | 0000711377-25-000052 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Ronald D. Green 2025-10-23 | Form 4 | 2025-10-27 | 0000711377-25-000052 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Jeffrey D. Capello 2025-10-23 | Form 4 | 2025-10-27 | 0000711377-25-000051 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Thierry L. Bernard 2025-10-23 | Form 4 | 2025-10-27 | 0000711377-25-000050 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, James C. Borel 2025-10-23 | Form 4 | 2025-10-27 | 0000711377-25-000049 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Thierry L. Bernard 2025-10-23 | Form 4 | 2025-10-27 | 0000711377-25-000050 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Catherine E. Woteki 2025-10-23 | Form 4 | 2025-10-27 | 0000711377-25-000056 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Aashima Gupta 2025-10-23 | Form 4 | 2025-10-27 | 0000711377-25-000053 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Jeffrey D. Capello 2025-10-23 | Form 4 | 2025-10-27 | 0000711377-25-000051 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, James C. Borel 2025-10-23 | Form 4 | 2025-10-27 | 0000711377-25-000049 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Andrea F. Wainer 2025-10-23 | Form 4 | 2025-10-27 | 0000711377-25-000055 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Avi Pelossof 2025-10-24 | Form 4 | 2025-10-28 | 0000711377-25-000058 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Avi Pelossof 2025-10-24 | Form 4 | 2025-10-28 | 0000711377-25-000058 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Ronald D. Green 2025-10-27 | Form 4 | 2025-10-29 | 0000711377-25-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, James C. Borel 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000059 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, David Naemura 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Aashima Gupta 2025-10-27 | Form 4 | 2025-10-29 | 0000711377-25-000069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, David Naemura 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, William T. Boehm 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, John Edward Adent 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, James C. Borel 2025-10-27 | Form 4 | 2025-10-29 | 0000711377-25-000072 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, James C. Borel 2025-10-27 | Form 4 | 2025-10-29 | 0000711377-25-000072 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Jeffrey D. Capello 2025-10-27 | Form 4 | 2025-10-29 | 0000711377-25-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Aashima Gupta 2025-10-27 | Form 4 | 2025-10-29 | 0000711377-25-000069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Raphael A. Rodriguez 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000068 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, James P. Tobin 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000067 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Catherine E. Woteki 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Amy Rocklin 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Amy Rocklin 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Amy Rocklin 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Douglas Jones 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Douglas Jones 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, John Edward Adent 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, John Edward Adent 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Jeffrey D. Capello 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000060 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, James C. Borel 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000059 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Raphael A. Rodriguez 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000068 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, James P. Tobin 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000067 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Catherine E. Woteki 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, William T. Boehm 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Douglas Jones 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, David Naemura 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Jeffrey D. Capello 2025-10-27 | Form 4 | 2025-10-29 | 0000711377-25-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Ronald D. Green 2025-10-27 | Form 4 | 2025-10-29 | 0000711377-25-000070 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Jeffrey D. Capello 2025-10-27 | Form 4 | 2025-10-28 | 0000711377-25-000060 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Mikhael Nassif 2025-11-03 | Form 4 | 2025-11-07 | 0000711377-25-000076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Richard Bryan Riggsbee 2025-11-03 | Form 4 | 2025-11-05 | 0000711377-25-000074 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Richard Bryan Riggsbee 2025-11-03 | Form 4 | 2025-11-05 | 0000711377-25-000074 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, David Naemura 2025-12-01 | Form 4 | 2025-12-02 | 0000711377-25-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, David Naemura 2025-12-01 | Form 4 | 2025-12-02 | 0000711377-25-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, David Naemura 2025-12-01 | Form 4 | 2025-12-02 | 0000711377-25-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Tamara A. Ranalli 2026-01-07 | Form 4 | 2026-01-29 | 0000711377-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Tamara A. Ranalli 2026-01-07 | Form 4 | 2026-01-26 | 0000711377-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Tamara A. Ranalli 2026-01-07 | Form 4 | 2026-01-29 | 0000711377-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Tamara A. Ranalli 2026-01-07 | Form 4 | 2026-01-26 | 0000711377-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Tamara A. Ranalli 2026-01-07 | Form 4 | 2026-01-29 | 0000711377-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Mikhael Nassif 2026-01-16 | Form 4 | 2026-01-16 | 0000711377-26-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Mikhael Nassif 2026-01-26 | Form 4 | 2026-02-02 | 0000711377-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Mikhael Nassif 2026-01-26 | Form 4 | 2026-02-02 | 0000711377-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Mikhael Nassif 2026-02-17 | Form 4 | 2026-02-17 | 0000711377-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Jennifer Evans Stacey 2026-05-01 | Form 4 | 2026-05-04 | 0000711377-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Jennifer Evans Stacey 2026-05-01 | Form 4 | 2026-05-04 | 0000711377-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, John Patrick Moylan 2026-05-04 | Form 4 | 2026-05-05 | 0000711377-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, John Patrick Moylan 2026-05-04 | Form 4 | 2026-05-05 | 0000711377-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, John Patrick Moylan 2026-05-04 | Form 4 | 2026-05-05 | 0000711377-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Amy Rocklin 2026-05-18 | Form 4 | 2026-05-19 | 0000711377-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Amy Rocklin 2026-05-18 | Form 4 | 2026-05-19 | 0000711377-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Amy Rocklin 2026-05-18 | Form 4 | 2026-05-19 | 0000711377-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, John Patrick Moylan 2026-06-03 | Form 4 | 2026-06-04 | 0000711377-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 06, 2025 vote | Form 8-K | 2025-10-27 | 0001193125-25-250823 | Item 5.07 · say-on-pay result. As reported: 90.43% (votes for as printed: 167,126,873). Filing ↗ |
| 133 | Section 06, 2024 vote | Form 8-K | 2024-10-28 | 0000950170-24-117710 | Item 5.07 · say-on-pay result. As reported: 48.76% (votes for as printed: 96,518,858). Filing ↗ |
| 134 | Section 06, 2023 vote | Form 8-K | 2023-10-31 | 0000950170-23-056922 | Item 5.07 · say-on-pay result. As reported: 96.72% (votes for as printed: 188,942,194). Filing ↗ |
| 135 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 136 | Section 09b board cost (computed) | Computed | — | computed | Cash 721,667 + equity 741,150 + all other 0 = 1,462,817, summed across the director compensation table rows.machine: formula: Σ = 1,462,817 |
| 137 | Exact Sciences Corporation, Section 10b CEO total | DEF 14A | 2025-04-29 | 0001124140-25-000034 | CEO total compensation as printed in Exact Sciences Corporation's own proxy. As printed: 15,539,378. Filing ↗machine: span 1077855–1077865 |
| 138 | Charles River Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-31 | 0001104659-26-037367 | CEO total compensation as printed in Charles River Laboratories, Inc.'s own proxy. As printed: 15,435,220. Filing ↗machine: r1 · c53 · span 1119658–1119668 |
| 139 | Natera, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047770 | CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878 |
| 140 | IDEXX Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0000874716-26-000064 | CEO total compensation as printed in IDEXX Laboratories, Inc.'s own proxy. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018 |
| 141 | Waters Corporation, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149657 | CEO total compensation as printed in Waters Corporation's own proxy. As printed: 13,973,044. Filing ↗machine: r5 · c18 · span 568522–568533 |
| 142 | QuidelOrtho Corporation, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001906324-26-000018 | CEO total compensation as printed in QuidelOrtho Corporation's own proxy. As printed: 11,255,782. Filing ↗machine: r4 · c24 · span 760612–760622 |
| 143 | Sotera Health Company, Section 10b CEO total | DEF 14A | 2026-04-08 | 0001104659-26-040937 | CEO total compensation as printed in Sotera Health Company's own proxy. As printed: 10,656,063. Filing ↗machine: span 996859–996869 |
| 144 | Azenta, Inc., Section 10b CEO total | DEF 14A | 2025-12-18 | 0001140361-25-046064 | CEO total compensation as printed in Azenta, Inc.'s own proxy. As printed: 10,371,414. Filing ↗machine: r2 · c22 · span 1247118–1247129 |
| 145 | Maravai LifeScience Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001823239-26-000014 | CEO total compensation as printed in Maravai LifeScience Holdings, Inc.'s own proxy. As printed: 10,129,708. Filing ↗machine: t21 · r3 · c20 · span 502645–502655 |
| 146 | NeoGenomics, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001077183-26-000014 | CEO total compensation as printed in NeoGenomics, Inc.'s own proxy. As printed: 9,127,092. Filing ↗machine: r2 · c45 · span 869460–869469 |
| 147 | Guardant Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187403 | CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. Filing ↗machine: r7 · c31 · span 773149–773158 |
| 148 | Bio-Techne Corporation, Section 10b CEO total | DEF 14A | 2025-09-19 | 0001308179-25-000599 | CEO total compensation as printed in Bio-Techne Corporation's own proxy. As printed: 8,151,181. Filing ↗machine: span 792074–792083 |
| 149 | Bio-Rad Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0000012208-26-000020 | CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. Filing ↗machine: r2 · c24 · span 654200–654209 |
| 150 | Neogen (subject), Section 10b CEO total | DEF 14A | 2025-09-12 | 0000950170-25-114381 | CEO total compensation as printed in Neogen's own proxy. As printed: 6,824,891. Filing ↗machine: r3 · c31 · span 1277142–1277151 |
| 151 | Mettler-Toledo International, Inc., Section 10b CEO total | DEF 14A | 2026-03-18 | 0001174947-26-000389 | CEO total compensation as printed in Mettler-Toledo International, Inc.'s own proxy. As printed: 6,741,212. Filing ↗machine: r2 · c7 · span 643529–643538 |
| 152 | Repligen Corporation, Section 10b CEO total | DEF 14A | 2026-04-02 | 0001193125-26-140115 | CEO total compensation as printed in Repligen Corporation's own proxy. As printed: 6,114,771. Filing ↗machine: t16 · r4 · c2 · span 577065–577074 |
| 153 | Bruker Corporation, Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-151305 | CEO total compensation as printed in Bruker Corporation's own proxy. As printed: 4,706,388. Filing ↗machine: t77 · r2 · c18 · span 987303–987312 |
| 154 | OraSure Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001116463-26-000032 | CEO total compensation as printed in OraSure Technologies, Inc.'s own proxy. As printed: 4,292,228. Filing ↗machine: t152 · r2 · c21 · span 850376–850385 |
| 155 | Section 10a, Sotera Health Company reciprocity | DEF 14A | — | 0001104659-26-040937 | Sotera Health Company's most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 156 | Section 10a, Maravai LifeScience Holdings, Inc. reciprocity | DEF 14A | — | 0001823239-26-000014 | Maravai LifeScience Holdings, Inc. names Neogen in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 157 | Section 10a, NeoGenomics, Inc. reciprocity | DEF 14A | — | 0001077183-26-000014 | NeoGenomics, Inc.'s most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 158 | Section 10a, Azenta, Inc. reciprocity | DEF 14A | — | 0001140361-25-046064 | Azenta, Inc.'s most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 159 | Section 10a, Waters Corporation reciprocity | DEF 14A | — | 0001193125-26-149657 | Waters Corporation's most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 160 | Section 10a, IDEXX Laboratories, Inc. reciprocity | DEF 14A | — | 0000874716-26-000064 | IDEXX Laboratories, Inc.'s most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 161 | Section 10a, OraSure Technologies, Inc. reciprocity | DEF 14A | — | 0001116463-26-000032 | OraSure Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 162 | Section 10a, Natera, Inc. reciprocity | DEF 14A | — | 0001104659-26-047770 | Natera, Inc.'s most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 163 | Section 10a, Charles River Laboratories, Inc. reciprocity | DEF 14A | — | 0001104659-26-037367 | Charles River Laboratories, Inc.'s most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 164 | Section 10a, Repligen Corporation reciprocity | DEF 14A | — | 0001193125-26-140115 | Repligen Corporation names Neogen in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 165 | Section 10a, Mettler-Toledo International, Inc. reciprocity | DEF 14A | — | 0001174947-26-000389 | Mettler-Toledo International, Inc.'s most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 166 | Section 10a, Guardant Health, Inc. reciprocity | DEF 14A | — | 0001193125-26-187403 | Guardant Health, Inc.'s most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 167 | Section 10a, Exact Sciences Corporation reciprocity | DEF 14A | — | 0001124140-25-000034 | Exact Sciences Corporation's most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 168 | Section 10a, QuidelOrtho Corporation reciprocity | DEF 14A | — | 0001906324-26-000018 | QuidelOrtho Corporation's most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 169 | Section 10a, Bio-Techne Corporation reciprocity | DEF 14A | — | 0001308179-25-000599 | Bio-Techne Corporation's most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 170 | Section 10a, Bruker Corporation reciprocity | DEF 14A | — | 0001193125-26-151305 | Bruker Corporation's most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |